Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia.
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood.2024024861
Abstract: Approximately 30% of acute myeloid leukemia (AML) patients express CD7 on their myeloblasts. We have previously demonstrated that scFv-based "naturally selected" CD7 CAR-T (NS7CAR-T) therapy shows significant efficacy with a favorable safety profile in T-cell… read more here.
Keywords: cd7; acute myeloid; ns7car; naturally selected ... See more keywords